Chenguang Biotech ordered to rectify by Xinjiang Securities Regulatory Bureau over subsidiary's 136 million yuan fund occupation

Regulation
โดย Jiemian·CN·Read original
Summary · why it matters

Chenguang Biotech Group was ordered by the Xinjiang Securities Regulatory Bureau to rectify and was issued a warning letter after a subsidiary's non-operating fund occupation of 136 million yuan. Between March and April 2025, the company received a total of 136 million yuan in intercompany loans from a wholly owned subsidiary of Xinjiang Shengyuan Biotechnology, a consolidated entity, and from Handan Chenguang Plant Protein. The funds were repaid with interest in May, constituting non-operating fund occupation. Xinjiang Shengyuan Biotechnology and its subsidiaries are entities within the company's consolidated statements, and on a look-through basis the company holds an 89.82 percent stake in it. The Xinjiang Securities Regulatory Bureau required the company to submit a written rectification report within 30 days and said the relevant measures will be recorded in the securities and futures market integrity archive. The company said it attaches great importance to the matter and will strengthen internal controls and financial management, adding that the measures do not affect normal production and operations.

Impact on stocks 1

Others▼ · 1 stocks
Chenguang Biotech Group
300138
▼ NegativeRegulationrelevance

Ordered to rectify and warned by securities regulator over subsidiary's 136 million yuan fund occupation.

Off-coverage companies 2

新疆晟源生物科技股份有限公司Private▼ Negative
Regulationrelevance

Subsidiary involved in non-operating fund occupation, subject to regulatory action.

邯郸晨光植物蛋白有限公司Private▼ Negative
Regulationrelevance

Subsidiary involved in non-operating fund occupation, subject to regulatory action.

© 2026 MarketDXNews